Short description
CYPRUMED is a biopharmaceutical company
Description
CYPRUMED® is a biopharmaceutical company developing a next generation platform technology for the oral delivery of polypeptides. The patent pending technology is entirely based on GRAS listed compounds and easy to formulate. In vivo studies with various polypeptide drugs in rodents, dogs and none human primates showed oral bioavailability up to 70% (rel. s.c.).
Last funding
Cannot Access
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Obsteig, Tirol, Austria, Europe
Founded on
January 1, 2015
Non-profit?
No
Acquired?
No
Employees count
1-10
Founders
Florian Föger